A novelty of this symposium was the presentation of case reports from daily practice by two German pharmacists with extensive experience in oncology pharmacy, Matthias Wriedt, Hamburg and Beatrix Ulrich, Bad Säckingen. Both cases illustrated possible pharmaceutical interventions.

Beatrix Ulrich presented the case of a 39 year old female patient with ovarian cancer who had been helped by intensive pharmaceutical interdisciplinary support during the process of diagnosis. Ulrich emphasized the importance of educating the patient regarding the drug therapy and providing the treating physician with information, in this case for antemetic drug treatment. Matthias Wriedt illustrated how important pharmacist support is even in complex cancer pathologies. He presented the case of a 38 year old male patient with a rare highly malignant B-cell lymphoma. The patient benefited greatly from the pharmaceutical care he received throughout his therapy. Wriedt highlighted the need for documentation. When assisting a patient over a long period it is important to keep track of the therapeutic development according to the SOAP (Subjective, Objective, Assessment, Plan) method. Both speakers stressed the importance of the pharmacist’s role as drug therapy consultant to the patient and the medical team. Both speakers encouraged pharmacists to take responsibility for their patients and contribute to their care in an interdisciplinary team.

New information was presented about current advances in radiotherapy and chemotherapy of cancer (Mikiciuk-Olasik E., Łódź; Wagner W., Osnabrück; Boss J., Münster), errors in cancer therapy (Justus H., Ludwigslust), and practical aspects of pharmaceutical care of cancer patients (Grzeszkowiak E., Poznań; Liekweg A., Hamburg).

The meeting also addressed cooperation when using off-label anticancer drugs and how to disseminate knowledge of their actions. Unlicensed drugs are often prescribed in oncology for their mechanism of action and properties in order to overcome tumour resistance to chemotherapy. As costs are high, there is pressure to limit or even discontinue their use in Poland (http://www.gazeta.pl). The central distribution of drugs by National Health Fund (NFZ) is insufficient and in many hospitals there is no money for pivotal drugs. The patient has to pay for the expensive drugs or the medical staff has to decide who will or will not be treated. In Germany, reimbursement by insurance companies has also been reduced by the expert group for adverse drug reactions (ADRs) and may limit the cost of drugs.

Insights into those complex mechanisms enable researchers to develop new treatment strategies. Such new strategies will be more targeted to the individual compared to conventional chemotherapy. As examples Lipski outlined future gene therapy, as well as groups of drugs that are already internationally licensed, such as Vascular Endothelial Growth Factor (VEGF) inhibitors. The variety of future therapeutic options which Lipski presented clarified the great challenge for oncology pharmacists to contribute to tailor made antineoplastic therapies for their patients.

However the high cost of oligonucleotide arrays (150 US$ per chip) and technical difficulties are still major obstacles to the widespread use of genetic tests. The application of tests to determine the usefulness of off-label drugs for individuals will be a subject for future consideration. All 130 participants from Germany and Poland left this meeting with renewed understanding and friendship. This is what we need for the further development of Europe!

Author for Correspondence
Klaus Meier
President of DGOP and ESOP
Landesbetrieb Krankenhäuser (LBK) Hamburg GmbH
Allgemeines Krankenhaus St. Georg
Lohmühlenstraße 5
D-20099 Hamburg, Germany
KHMeeier@t-online.de
Estimating the Incremental Costs Associated with Nosocomial Infections
Medical Care, June 1987, 25 (6): 481-8

Pharmaceutical industry. Antibiotics and hazards for the worker.
33. Davies RJ, Hendrick DJ, Pepys J.
Asthma due to inhaled chemical agents: ampicillin, benzyl penicillin, 6 amino penicillanic acid and related substances.
34. Davies RJ, Pepys J
Asthma due to inhaled chemical agents – the macrolide antibiotic Spiramycin
Asthma in workers manufacturing cephalosporins
Occupational asthma, rhinitis and urticaria due to piperacillin sodium in pharmaceutical worker.
Eur Respir J. 1995 Mar;8(3):467-9
37. Stenton SC, Dennis JH, Hendrick DJ
Occupational asthma due to ceftazidime
Eur Respir J. 1995 Aug;8(3):1421-3
38. Sastre J, Quirce S, Novalbos A, Lluch-Bernal M,
Bombin C, Umpierrez A.
Occupational asthma induced by cephalosporins
Eur Respir J. 1999 May;13(5):1189-91
Vapour pressures, evaporation behaviour and airborne concentrations of hazardous drugs: implications for occupational safety.
The Pharmaceutical Journal, 2002 vol. 268 March;332-337
40. Nicholas S, Brown D, Short C
Evaluation of the Baxter Minibag Plus for ward preparation of cefuroxime/metronidazole infusion mixtures
Hospital Pharmacist 2000 Nov;297-300